Ascelia Pharma AB (publ) (STO:ACE)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.720
+0.045 (0.96%)
Aug 26, 2025, 4:57 PM CET
0.96%
Market Cap543.58M
Revenue (ttm)n/a
Net Income (ttm)-94.78M
Shares Out116.03M
EPS (ttm)-1.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume607,172
Average Volume956,499
Open4.695
Previous Close4.675
Day's Range4.620 - 4.800
52-Week Range2.000 - 5.230
Beta1.03
RSI49.76
Earnings DateAug 21, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACE
Full Company Profile

Financial Performance

Financial Statements

News

Ascelia Pharma AB (FRA:7ZA) Q2 2025 Earnings Call Highlights: Strategic Moves and Market ...

Ascelia Pharma AB (FRA:7ZA) Q2 2025 Earnings Call Highlights: Strategic Moves and Market Potential for Orviglance

3 days ago - GuruFocus

Q2 2025 Ascelia Pharma AB Earnings Call Transcript

Q2 2025 Ascelia Pharma AB Earnings Call Transcript

3 days ago - GuruFocus